-
US threatens 'devastating' response to any Iran attack on shipping
-
Murphy warns snooker hopefuls to 'work harder' to match Chinese stars
-
Race to find port for hantavirus-stricken cruise ship
-
Romanian pro-EU PM loses no-confidence motion
-
Stocks diverge as traders eye US-Iran ceasefire
-
Edin Terzic to become Athletic Bilbao coach next season
-
Borthwick backed by RFU to take England to 2027 Rugby World Cup
-
EU hails 'leap forward' in ties with Russia's ally Armenia
-
German car-ramming suspect had mental health problems: reports
-
Pyongyang calling: North Korea shows off own-brand phones
-
Iran warns 'not even started' in Hormuz
-
World body in dark over allegations against China badminton chief
-
Asian stocks drop amid fears over US-Iran ceasefire
-
China fireworks factory explosion kills 26, injures 61
-
China hails 'our era' as Wu Yize's world snooker triumph goes viral
-
Ex-model accuses French scout of grooming her for Epstein
-
Timberwolves eclipse Spurs as Knicks rout Sixers
-
Taiwan leader says island has 'right to engage with the world'
-
Yoko says oh no to 'John Lemon' beer
-
Bayern's Kompany promises repeat fireworks in PSG Champions League semi
-
A coaching great? Luis Enrique has PSG on brink of another Champions League final
-
Top five moments from the Met Gala
-
Brunson leads Knicks in rout of Sixers
-
Retiring great Sophie Devine wants New Zealand back playing Tests
-
Stocks sink amid fears over US-Iran ceasefire
-
G7 trade ministers set to meet but not discuss latest US tariff threat
-
Sherlock Holmes fans recreate fateful duel at Swiss falls
-
Premier League losses soar for clubs locked in 'arms race'
-
'Spreading like wildfire': Fiji grapples with soaring HIV cases
-
For Israel's Circassians, food and language sustain an ancient heritage
-
'Super El Nino' raises fears for Asia reeling from Middle East conflict
-
Trouble in paradise: Colombia tourist jewel plagued by violence
-
Death toll in Brazil small plane crash rises to three
-
Pulitzers honor damning coverage of Trump and his policies
-
Digi Power X Signs AI Colocation Agreement with Leading AI Compute Company for 40 MW Data Center in Columbiana, Alabama
-
LA fire suspect had grudge against wealthy: prosecutors
-
US-Iran ceasefire on brink as UAE reports attacks
-
Stars shine at Met Gala, fashion's biggest night
-
Birthday girl, 10, among dead in Colombia monster truck crash
-
Blake Lively, Justin Baldoni agree to end lengthy legal battle
-
Dolly Parton cancels Las Vegas shows over health concerns
-
Wu Yize: China's 'priest' who conquered the snooker world
-
China's Wu Yize wins World Snooker Championship for first time
-
Broadway theater blaze forces 'Book of Mormon' to close
-
Advantage Arsenal as Man City held in six-goal Everton thriller
-
Roma hammer Fiorentina to remain in Champions League hunt
-
MLB Tigers star pitcher Skubal to undergo elbow surgery
-
Oil prices jump on Hormuz tensions as US indices retreat from records
-
No.6 Morikawa withdraws from final PGA Championship tuneup
-
Ukraine and Russia declare separate truces
US FDA says Pfizer Covid vaccine effective in kids under five
The US Food and Drug Administration (FDA) has said the Pfizer Covid vaccine is safe and effective in children under five, ahead of a meeting to weigh its authorization later this week.
Children under five are the only age group not yet eligible for vaccination in the United States and most countries, a pressing need since rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age," the FDA said in a document posted on its website Sunday.
The agency has called a meeting of experts on June 15 to decide whether to recommend the Pfizer vaccine, given as three shots to children aged six months through four years, as well as the Moderna vaccine, given as two shots to children aged six months through five years.
Pfizer's first two shots are given three weeks apart, then the third is given eight weeks after the second. They are all dosed at three micrograms, as opposed to 30 micrograms the company gives older ages.
Both Pfizer and Moderna had previously posted their results, but the FDA then had to review the data in detail and carry out its own evaluation. It posted a favorable analysis about Moderna on Friday.
Its comments towards Pfizer also appear favorable, based on the levels of infection-blocking antibodies it evoked in trial participants, and a similar side-effect profile to higher age groups. The trial population was around 4,500 children.
A preliminary estimate placed vaccine efficacy at 80.3 percent, but the FDA noted this was based on very few positive cases -- just 10, as opposed to the 21 sought for a more accurate figure.
There are nearly 20 million US children aged four years and under, or six percent of the population. If, as expected, the FDA-appointed experts recommend the two shots, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
N.Fournier--BTB